Intracranial aneurysm

Global Intracranial Aneurysm Market Research Report to 2027 - by Type, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, March 25, 2022
Health, General Health, CAGR, Market share analysis, USD, Strategic management, Investment, Customer support, Growth, Certification, Intracranial aneurysm, Global, Use, COVID-19, Business Growth Fund, Value, R, Acquisition, Decision-making, Retail, Fine chemical

What is the market size and forecast of the Global Intracranial Aneurysm Market?

Key Points: 
  • What is the market size and forecast of the Global Intracranial Aneurysm Market?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Intracranial Aneurysm Market?
  • What is the market share of the leading vendors in the Global Intracranial Aneurysm Market?
  • What modes and strategic moves are considered suitable for entering the Global Intracranial Aneurysm Market?

Cerus Endovascular Receives U.S. Food and Drug Administration 510(k) Clearance of its 027 Micro-catheter

Retrieved on: 
Wednesday, March 23, 2022
Sale, Intracranial aneurysm, Neck, Medical Device Regulation Act, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), Aneurysm, CE marking, Food, Food and Drug Administration, Mark (given name), Research and development, FDA, System, Medical device, Mobile phone, Medical imaging, Pharmaceutical industry, EU

FREMONT, Calif. and OXFORD, England, March 23, 2022 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its 027 micro-catheters, available in two lengths, expanding its product portfolio which includes the already FDA cleared 021 micro-catheter platform. The company expects to submit for CE Marking of both sizes under the EU new Medical Devices Regulation, later this year.

Key Points: 
  • The company expects to submit for CE Marking of both sizes under the EU new Medical Devices Regulation, later this year.
  • Cerus Endovascular also announced today that it is expanding the size offerings of its Contour Neurovascular System platform.
  • "The continued expansion of our portfolio and the increased market penetration are key elements of our ongoing commercialization strategy," stated Dr. Sam Milstein, Chairman of Cerus Endovascular.
  • Enrollment in the Cerus Endovascular IDE trial in the United States continues as scheduled."

Viz.ai Debuts Viz ANX, the First AI-powered Cerebral Aneurysm Detection Solution at SVIN 2021

Retrieved on: 
Wednesday, November 17, 2021
Technology, Medical Devices, Hospitals, Other Technology, Clinical Trials, Cardiology, Software, Biotechnology, Health, Data Management, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Rupture, Physician, Society, Silicon, Neuroradiology, MMA, Triage, Aneurysm, Medtronic, Food, Stroke, Forbes, Diffusion, CEO, Bleeding, Neuroscience, Hospital, GV (company), Scale Venture Partners, Research, LES, Subdural hematoma, Grady Memorial Hospital, CTAS, CRV, Insight Partners, Annual general meeting, SDH, FDA, Multimedia, Intelligence, Patient, De novo, Safety, Technology, Deep learning, Anatomy, Federal Food, Drug, and Cosmetic Act, Intracranial aneurysm, Cuban Neuroscience Center, Intracranial hemorrhage, Veni, vidi, vici, 3D, Health, Viz, Eric Schmidt, Medical device, Medical imaging

The Viz Platform is now utilized in over 850 hospitals across the U.S. and Europe and touches almost two patients every minute.

Key Points: 
  • The Viz Platform is now utilized in over 850 hospitals across the U.S. and Europe and touches almost two patients every minute.
  • Cerebral aneurysm is challenging to detect and treat because current care pathways are complex and rely on manual identification and triage.
  • Viz.ai will showcase the new Viz ANX and Viz SDH, along with the rest of the Viz Intelligent Care Coordination Platform, at SVIN 2021.
  • Also in 2021, the FDA cleared the Viz PE and Viz Aortic modules, making the Viz Platform multi-disciplinary.

Brainomix partners with Wallaby Medical to bring the most comprehensive AI stroke imaging solution to China

Retrieved on: 
Monday, September 27, 2021
Partnership, Suite, Department of Neurology, Xuanwu hospital, Capital University of Medical Sciences, Solution, Stroke, Precision medicine, Patient, Intracranial aneurysm, Physician, Health, University, Esperance, LinkedIn, Adult, Biomarker, Thrombectomy, Hospital, Twitter, Wallaby, CEO, Medical device, Pharmaceutical industry

As part of the agreement, Wallaby will distribute Brainomix's e-Stroke software to stroke centres across Greater China.

Key Points: 
  • As part of the agreement, Wallaby will distribute Brainomix's e-Stroke software to stroke centres across Greater China.
  • Stroke accounts for over 1.79 million deaths[1] annually in China and is one of the leading causes of adult disability.
  • With this partnership, Wallaby will bring the most comprehensive AI stroke imaging software solutions to support fast and accurate treatment decisions in Chinese hospitals.
  • Brainomix AI analysis and thrombectomy are the 'perfect couple' to combine together for the best treatment for stroke patients."

MCRA Expands Neurology Division into Neurointerventional Market

Retrieved on: 
Wednesday, September 22, 2021
Elective surgery, Stroke, Contract research organization, Quality assurance, Dural arteriovenous fistula, VB, FDA, Patient, Engineering, Intracranial aneurysm, Neurosurgery, IVD, Hydrocephalus, Food and Drug Administration, General surgery, Computer security, LLC, Neurology, MCRA, Idiopathic intracranial hypertension, Trial of the century, Journal of NeuroInterventional Surgery, DC, Boston Scientific, Technology, Research, Epidural hematoma, CRO, Robotics, Spine, Industry, Google Images, Medical device

Herrmann also had significant interactions onapplications for the clinical use ofdrug and biologic baseddevice combination products during his time with the agency.

Key Points: 
  • Herrmann also had significant interactions onapplications for the clinical use ofdrug and biologic baseddevice combination products during his time with the agency.
  • Dr. Herrmann said "I am very excited to join the highly distinguished team at MCRA and expand their regulatory expertise in the area of neurointerventional devices.
  • About MCRA, LLC:MCRA is the leading privately held independent medical device and biologics Clinical Research Organization (CRO) and advisory firm.
  • MCRA has offices in Washington, DC, Hartford, CT, and New York, NY, and serves more than 700 clients globally.

ZOLL and Wallaby Medical Announce Agreement to Distribute Temperature Management Products in China

Retrieved on: 
Monday, August 23, 2021
Other Manufacturing, Technology, Medical Devices, Other Technology, Cardiology, Software, Manufacturing, Other Health, Hardware, Health, EMS, National Academies Press, Indian Journal of Critical Care Medicine, Wallaby, Stroke, Ammonia, Time, Critical Care Medicine (journal), GBD, Survival, Life, Intracranial aneurysm, Esperance, Dialysis, Asahi Kasei, The Lancet, Data management, Ventilation, National Academy of Medicine, Cardiac arrest, Health, National academy, Hamad Medical Corporation, Temperature, Health care, Patient, TTM, Survivor, Solution, CEO, Howard Johnson Co. v. Detroit Local Joint Executive Board, FDA, CPR, Medical device, Pharmaceutical industry, ZOLL Medical Corporation, Asahi Kasei, Wallaby Medical, ZOLL MEDICAL CORPORATION, ASAHI KASEI, WALLABY MEDICAL

ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Wallaby Medical Technologies, a medical device company dedicated to treating stroke and cardiac arrest, today announced they have signed a distribution agreement whereby Wallaby will manage the sales and distribution of ZOLLs temperature management products in China.

Key Points: 
  • ZOLL Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, and Wallaby Medical Technologies, a medical device company dedicated to treating stroke and cardiac arrest, today announced they have signed a distribution agreement whereby Wallaby will manage the sales and distribution of ZOLLs temperature management products in China.
  • ZOLL is excited to work with Wallaby to further expand the use of the Thermogard XP in China, allowing more patients to benefit from high-quality targeted temperature management (TTM), said Neil Johnston, President, ZOLL Circulation.
  • The Thermogard XP Intravascular Temperature Management System is an important part of our comprehensive product portfolio to achieve that aim, said Michael Alper, CEO, Wallaby Medical.
  • IVTM, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries.

KANEKA CORPORATION: Sales Expansion of Brain Aneurysm Embolization Coils in the United States

Retrieved on: 
Friday, July 9, 2021
Health, Chemicals, Plastics, FDA, Medical devices, Surgery, Manufacturing, Other Manufacturing, Medical specialties, Neurosurgery, Cerebrovascular diseases, Branches of biology, Nervous system, Neurotrauma, Vascular diseases, Intracranial aneurysm, Aneurysm, Subarachnoid hemorrhage, Stroke, Kaneka Corporation

Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.

Key Points: 
  • Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.
  • Kaneka Medical America has been promoting the product at major stroke centers in the U.S., the worlds largest market.
  • It is deployed into the aneurysm through a catheter to prevent blood flow into the aneurysm.
  • A brain aneurysm is a bump that develops in an artery of the brain, and if it ruptures, it can cause subarachnoid hemorrhage.

Global Intracranial Aneurysm Market (2021 to 2028) - Share, Size, Trends, Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Health, Other Health, Medical specialties, Neurosurgery, Angiology, Cardiovascular system, Vascular diseases, Cerebrovascular diseases, Intracranial aneurysm, Aneurysm

b'The "Intracranial Aneurysm Market Share, Size, Trends, Industry Analysis Report, By Type, By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global intracranial aneurysm market size is expected to reach USD 2.32 billion by 2028 according to a new study.

Key Points: 
  • b'The "Intracranial Aneurysm Market Share, Size, Trends, Industry Analysis Report, By Type, By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global intracranial aneurysm market size is expected to reach USD 2.32 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nMarket factors favoring the market growth for intracranial aneurysm include the world\'s aging population, rising prevalence of intracranial aneurysms, sedentary and busy lifestyles, increased funding, and grant on research and innovation.
  • This large section of the population is largely contributing to the market growth.
  • As per the estimates of the BAF, in the U.S. alone, every year around 30,000 people live with brain aneurysms.

Medtronic Receives U.S. FDA Approval for Pipeline™ Flex Embolization Device with Shield Technology™

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Interventional radiology, Medicine, Vascular diseases, Neurosurgery, Interventional Neuroradiology, Medical imaging, Aneurysm, Medtronic, Embolization, Intracranial aneurysm, NYU Langone Health

b'First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health\nDUBLIN, April 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline Flex Embolization Device with Shield Technology.

Key Points: 
  • b'First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health\nDUBLIN, April 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline Flex Embolization Device with Shield Technology.
  • NYU Langone Health in New York City performed the first patient procedure in the nation with the new device.\nCelebrating its 10-year anniversary in the U.S. in 2021, Pipeline Flex Embolization Device diverts blood flow away from a brain aneurysm.
  • "\nPublished on June 1, 2020, in the Journal of NeuroInterventional Surgery (JNIS), results from the SHIELD Study (Periprocedural to 1-year safety and efficacy outcomes with the Pipeline Embolization Device with Shield technology for intracranial aneurysms: a prospective, post-market, multi-center study) demonstrate that the third-generation Pipeline Flex Embolization Device with Shield Technology continues the strong record of safety and efficacy of flow diversion therapy with the Medtronic family of products.
  • "Ten years ago, Medtronic changed the treatment paradigm in brain aneurysms with the approval of Pipeline Embolization Device, and we continue to challenge ourselves to deliver solutions that improve outcomes and increase value for all healthcare stakeholders.

Cerus Endovascular Announces IDE Approval from the U.S. FDA to Conduct Clinical Study of the Contour Neurovascular System™

Retrieved on: 
Wednesday, April 21, 2021
Medical specialties, Vascular diseases, Neurosurgery, Interventional radiology, Flow diverter, Prosthetics, Cerebrovascular diseases, Aneurysm, Intracranial aneurysm, Embolization, Alexander L. Coon

"The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval.

Key Points: 
  • "The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval.
  • Given the real-world patient outcomes we have experienced in Europe, where the Contour Neurovascular System has had CE mark approval since March 2020, we are hopeful that we will see similar, strong results from this trial.
  • "\nThe study, is designed to develop a robust data set to support the safety and efficacy of the Contour Neurovascular System for the endovascular embolization of wide-necked, bifurcated, saccular intracranial aneurysms.
  • The Company\'s CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, expand the number and types of treatable intracranial aneurysms.